Open main menu

Psychiatrienet β

Hypericum-clomipramine

Revision as of 14:31, 7 May 2009 by Alexandra (talk | contribs)
Hypericum
Type Antidepressant
Group other
links
EMEA 10130408en
PubMed Hypericum
Kompas (Dutch) hypericum extract
Wikipedia St John's wort
Clomipramine
Type Antidepressant
Group TCA
links
ATC-code N06AA04
Medscape Clomipramine
PubChem 2801
PubMed Clomipramine
Kompas (Dutch) Clomipramine
Wikipedia Clomipramine

Switch medication from hypericum to clomipramine.[1] [2]

Nietinrijdenbord.png Stop hypericum
  • Administration of hypericum can be stopped abruptly.
Eenrichtingbord.png Start clomipramine
  • Day 1-7: a wash-out period of one week is necessary.
  • Day 8: start administration of clomipramine in a dosage of 50 mg/day.
  • If necessary, increase dosage of clomipramine to 75 mg/day.
  • Start low, go slow.
Infobord.png More information
  • Occurrence of the serotonin syndrome is theoretically possible.
  • Hypericum slows the metabolism of clomipramine via CYP3A4. This effect may persist up to two weeks after stopping hypericum, so caution is necessary.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.